Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
出版年份 2021 全文链接
标题
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
作者
关键词
-
出版物
Lancet Gastroenterology & Hepatology
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-09-22
DOI
10.1016/s2468-1253(21)00300-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
- (2020) Kenneth Cusi DIABETES CARE
- Therapeutic landscape for NAFLD in 2020
- (2020) Brent A. Neuschwander-Tetri GASTROENTEROLOGY
- The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
- (2020) F. Anthony Romero et al. JOURNAL OF MEDICINAL CHEMISTRY
- Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis
- (2020) Maya Balakrishnan et al. Clinical Gastroenterology and Hepatology
- Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
- (2020) Jonathan G. Stine et al. Clinical Gastroenterology and Hepatology
- Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes
- (2020) Zobair M. Younossi et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- AMP-activated protein kinase: the current landscape for drug development
- (2019) Gregory R. Steinberg et al. NATURE REVIEWS DRUG DISCOVERY
- Sex Differences in NAFLD : State of the Art and Identification of Research Gaps
- (2019) Amedeo Lonardo et al. HEPATOLOGY
- Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States
- (2019) Zobair M. Younossi et al. DIABETES CARE
- Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
- (2019) Fernando Bril et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
- (2019) Gordon I. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Promise and challenges for direct small molecule AMPK activators
- (2018) Séverine Olivier et al. BIOCHEMICAL PHARMACOLOGY
- Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
- (2018) Norbert Stefan et al. Lancet Diabetes & Endocrinology
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- AMPK: guardian of metabolism and mitochondrial homeostasis
- (2017) Sébastien Herzig et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Treatment of nonalcoholic fatty liver disease: role of AMPK
- (2016) Brennan K. Smith et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Current efforts and trends in the treatment of NASH
- (2015) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
- (2014) Anila K. Madiraju et al. NATURE
- Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging
- (2013) Xiaodong Zhong et al. MAGNETIC RESONANCE IN MEDICINE
- Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle
- (2011) I. Chopra et al. DIABETOLOGIA
- Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans
- (2010) Marie-Soleil Gauthier et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- AMPK inhibition in health and disease
- (2010) Benoit Viollet et al. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
- An energetic tale of AMPK-independent effects of metformin
- (2010) Russell A. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
- (2009) P. Aschner et al. DIABETES OBESITY & METABOLISM
- Visceral fat: A key mediator of steatohepatitis in metabolic liver disease
- (2008) David van der Poorten et al. HEPATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now